Rating Change
Maxim Group analysts initiated coverage on Rein Therapeutics Inc. (NASDAQ:RNTX) with a Buy rating on July 20, 2026.
new coverageNASDAQ:RNTX
Maxim Group Initiates Coverage on Rein Therapeutics Inc. (RNTX) with Buy
Rating Change Maxim Group analysts initiated coverage on Rein Therapeutics Inc. (NASDAQ:RNTX) with a Buy rating on July 20, 2026. Market Context Rein Therapeutics Inc.
Market Context
Rein Therapeutics Inc. operates in the Healthcare sector. The stock currently trades at $0.84 with a market capitalization of $40.2M.
Analyst coverage from Maxim Group provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Rein Therapeutics Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Rein Therapeutics Inc.
Among the 5 most recent ratings: 3 Buy, 2 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 20, 2026 | Maxim Group | Buy | N/A |
| Jun 01, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jan 21, 2026 | Brookline Capital | Hold | N/A |
| Sep 22, 2025 | HC Wainwright & Co. | Buy | N/A |
| Aug 19, 2025 | Brookline Capital | Hold | N/A |
Related Tools: Analyst Ratings Dashboard | View RNTX Stock Page
Frequently Asked Questions
What does a Buy rating mean for RNTX?
A Buy rating from Maxim Group reflects the analyst's outlook on Rein Therapeutics Inc. (NASDAQ:RNTX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RNTX forecast page.